摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-benzo[d]imidazol-1-yl)benzonitrile | 581081-62-1

中文名称
——
中文别名
——
英文名称
4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-benzo[d]imidazol-1-yl)benzonitrile
英文别名
4-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]benzonitrile
4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-benzo[d]imidazol-1-yl)benzonitrile化学式
CAS
581081-62-1
化学式
C16H10N6O
mdl
——
分子量
302.295
InChiKey
SGHQPTXSHFASJK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    23
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    107
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

  • 作为产物:
    参考文献:
    名称:
    4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors
    摘要:
    We report herein the design and synthesis of 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine derivatives as inhibitors of p70S6 kinase. Screening hits containing the 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine scaffold were optimized for p70S6K potency and selectivity against related kinases. Structure-based design employing an active site homology model derived from PKA led to the preparation of benzimidazole 5-substituted compounds 26 and 27 as highly potent inhibitors (K-i < 1 nM) of p70S6K, with > 100-fold selectivity against PKA, ROCK and GSK3. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.07.022
点击查看最新优质反应信息

文献信息

  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3
    申请人:Harbeson L. Scott
    公开号:US20070270420A1
    公开(公告)日:2007-11-22
    The present invention relates to compounds of formula I useful as inhibitors of GSK-3 and Lck protein kinases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes, Alzheimer's disease, and transplant rejection.
    本发明涉及一种公式I的化合物,其可用作GSK-3和Lck蛋白激酶的抑制剂。本发明还提供了包含该发明化合物的药学上可接受的组合物,并提供了使用这些组合物治疗和预防各种疾病的方法,例如糖尿病、阿尔茨海默病和移植排斥反应。
  • 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors
    作者:Upul Bandarage、Brian Hare、Jonathan Parsons、Ly Pham、Craig Marhefka、Guy Bemis、Qing Tang、Cameron Stuver Moody、Steve Rodems、Sundeep Shah、Chris Adams、Jose Bravo、Emmanuelle Charonnet、Vladimir Savic、Jon H. Come、Jeremy Green
    DOI:10.1016/j.bmcl.2009.07.022
    日期:2009.9
    We report herein the design and synthesis of 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine derivatives as inhibitors of p70S6 kinase. Screening hits containing the 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine scaffold were optimized for p70S6K potency and selectivity against related kinases. Structure-based design employing an active site homology model derived from PKA led to the preparation of benzimidazole 5-substituted compounds 26 and 27 as highly potent inhibitors (K-i < 1 nM) of p70S6K, with > 100-fold selectivity against PKA, ROCK and GSK3. (C) 2009 Elsevier Ltd. All rights reserved.
查看更多